In phase II, randomized, multicenter, I-SPY2 trial, in which patients with early hormone receptor (HR)-negative/HER-2 positive breast cancer and triple-negative breast cancer (TNBC) received neoadjuvant treatment with MK-2206 plus standard therapy (versus placebo plus standard therapy), pathological complete responses were associated with high pre-treatment levels of pAKT, pSGK, pmTOR, and pTSC2, in the HER-2 positive subset only, as determined by phosphoproteomic analyses. Here, ERBB2 is linked to breast cancer.